20945-53-3

Basic information

• Product Name: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE
• Synonyms: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE;(S)-2-[(Benzyloxycarbonyl)amino]-3-(1H-pyrazol-1-yl)propanoic acid;N-Cbz-3-(Pyrazol-1-yl)-L-alanine;Z-3-(Pyrazol-1-yl)-L-Ala-OH
• CAS NO: 20945-53-3
• Molecular Formula: C₁₄H₁₅N₃O₄
• Molecular Weight: 289.29
• Mol File: 20945-53-3.mol

Chemical Properties

• Boiling Point: 533.1±50.0 °C(Predicted)
• Appearance: /
• Density: 1.31
• PKA: 3.49±0.10(Predicted)
• CAS DataBase Reference: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(CAS DataBase Reference)
• NIST Chemistry Reference: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(20945-53-3)
• EPA Substance Registry System: L-N-CBZ-3-PYRAZOL-1-YL-ALANINE(20945-53-3)

Safety Data

• Hazardous Substances Data: 20945-53-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is used as a building block for the synthesis of various pharmaceutical drugs and research compounds. Its unique pyrazole ring structure allows for the creation of novel drug molecules with potential therapeutic applications.
Used in Biochemistry Research:
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is utilized in the study of protein structure and function. Its incorporation into protein molecules can provide insights into the role of amino acids in protein folding, stability, and function.
Used in Drug Development and Discovery:
L-N-CBZ-3-PYRAZOL-1-YL-ALANINE is employed in drug development and discovery processes. Its unique properties can be leveraged to design and develop new drugs with improved efficacy, selectivity, and safety profiles.

Upstream product

• 172749-95-0 (S)-benzyl 2-oxooxetan-3-ylcarbamate 
• 288-13-1 NH-pyrazole 
• 26054-60-4 ((S)-2-Oxo-oxetan-3-yl)-carbamic acid benzyl ester 

Downstream Products

• 149269-90-9 (S)-α-amino-N-[(1S,2R,3S)-1-(cyclohexylmethyl)-3-cyclopropyl-2,3-dihydroxypropyl]-3-(pyrazol-1-yl)propionamide 

Relevant articles and documents

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to methods for making compounds useful in the treatment of Hepatitis C virus (HCV) infection.

HEPATITIS C VIRUS INHIBITORS

The present disclosure relates to compounds, compositions and methods for the treatment of Hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

Hepatitis C Virus Inhibitors

The present disclosure relates to compounds, compositions and methods for the treatment of hepatitis C virus (HCV) infection. Also disclosed are pharmaceutical compositions containing such compounds and methods for using these compounds in the treatment of HCV infection.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) or Formula (II) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.